Aseptic Process Simulation / Media-Fill Support
A media fill validates the process—not just the filled units.
PlumGXP provides end-to-end aseptic process simulation support for pharmaceutical manufacturers, 503B outsourcing facilities, biotechnology operations and cell and gene therapy programs—from protocol strategy and pre-fill growth promotion through continuous monitoring, 14-day incubation, inspection and final reporting.
One contaminated vial can call the entire simulation into question.The right partner must understand the production process, the personnel risks, the environmental data and the microbiology behind every unit—not merely provide incubator space.
A True Extension of Your Team
More than putting vials in an incubator.
A credible APS challenges the complete aseptic operation under representative and appropriately difficult conditions. PlumGXP can supply the laboratory capacity and onsite microbiology resources many facilities do not maintain internally.
Designing the Challenge
Worst case is not one variable at a time.
The simulation should integrate the conditions that create the greatest contamination risk and reflect the complete process, including routine and corrective interventions.
A robust APS considers the interaction of:
PlumGXP Capabilities
Support across the entire APS lifecycle.
Select the services you need or engage PlumGXP for an integrated program.
APS strategy and protocol review
Process mapping, risk assessment, line configuration, fill volume, unit count, interventions, duration, personnel and sampling design.
Pre-fill growth promotion
Challenge the selected medium with suitable organisms before the APS to demonstrate that it is capable of supporting microbial growth.
Onsite execution support
Microbiology resources to help coordinate sampling, interventions, documentation and sample accountability throughout the fill.
Continuous process monitoring
Viable and nonviable monitoring aligned with the APS, including air, surface and personnel samples and documented event timing.
Incubation and inspection
Capacity for the complete lot, controlled incubation, interim checks, final inspection and reconciliation of every filled unit.
Identification and investigation
Organism identification and integration of personnel, environmental, intervention and process data when growth is detected.
Gowning qualification
Initial and periodic qualification support using defined sampling sites, limits, observations and documented technique assessment.
Personnel monitoring
Glove/fingertip and gown sampling performed at scientifically meaningful points, with results tied to operators and activities.
Final documentation
Complete data package, deviations, incubation records, inspection results, environmental correlation and summary reporting.
Reduce Risk Before the APS
Prove the medium works before you risk the fill.
Growth promotion is not an afterthought. Testing the selected media before execution provides evidence that it can support the growth of low levels of appropriate microorganisms under the planned conditions.
Discovering unsuitable media after the simulation can compromise interpretation, consume production time and force a repeat. PlumGXP performs pre-use growth promotion and can complete the required post-incubation growth-promotion testing as part of the final APS assessment.
Incubation + Inspection
Fourteen days of controlled evidence.
APS units cannot simply be placed in an incubator and forgotten. Their orientation, exposure to media, incubation conditions, inspection and reconciliation all affect the defensibility of the study.
Receive and reconcile
Document quantities, condition, traceability and any units rejected before incubation under pre-approved criteria.
Ensure media contact
Invert, swirl or otherwise manipulate integral units as appropriate so growth medium contacts the internal surfaces of the container and closure.
Incubate under defined conditions
Maintain the validated temperature sequence and duration—generally not less than 14 days—with continuous temperature control.
Check at defined intervals
Perform scheduled observations so suspected growth, damaged units or incubation issues are identified and documented promptly.
Inspect every unit
Trained, qualified personnel examine the units under suitable conditions, followed by independent verification when required by procedure.
Complete growth promotion
Demonstrate at the end of incubation that the medium remains capable of supporting growth, then finalize reconciliation and reporting.
Gowning + Personnel Monitoring
The people performing the process are part of the validation.
A successful APS must be supported by qualified operators whose gowning and aseptic behaviors are observed, monitored and traceable to the activities they perform.
Gowning qualification
PlumGXP can support initial qualification, periodic requalification and remediation following an adverse result or observed technique concern.
- Observed gowning sequence and aseptic behaviors
- Glove/fingertip and defined gown-location sampling
- Incubation, enumeration and identification when required
- Operator-specific records, trends and qualification status
Personnel monitoring during APS
Sampling is planned around what each operator actually did—not treated as a disconnected end-of-shift activity.
- Monitoring after critical interventions and at process completion
- Traceability to operator, location, time and activity
- Correlation with viable air, surface and particle data
- Escalation and organism identification for adverse recovery
Regulatory Framework
FDA, EU GMP Annex 1 and PDA TR-22.
Facilities serving US and EU markets need a protocol that recognizes where the expectations align—and where Annex 1 is more explicit.
| Focus | FDA Aseptic Processing Guidance | EU GMP Annex 1 | PDA TR-22 (Revised 2025) |
|---|---|---|---|
| Role | FDA guidance describing CGMP expectations for sterile drugs produced by aseptic processing. | EU GMP requirements for manufacture of sterile medicinal products. | Industry technical guidance for scientifically sound APS design, execution and lifecycle management; not itself a regulation. |
| Initial qualification | Generally, three consecutive successful runs per line or process. | At least three consecutive satisfactory APS runs covering all working shifts. | Risk- and science-based process simulation design supporting initial qualification and continued verification. |
| Routine frequency | Normally at least semiannually for each processing line, with each shift and operator addressed. | Normally twice a year for each aseptic process, filling line and shift; each operator should participate at least annually. | Frequency justified through lifecycle knowledge, risk, process changes and performance history while meeting applicable regulations. |
| Interventions | Representative routine and worst-case activities, including line stoppages and interventions. | All aseptic operations and relevant interventions, including inherent and corrective interventions, at appropriate frequency. | Detailed risk-based intervention selection and challenge design tied to the actual process. |
| Incubation | Generally 14 days using suitable temperatures; FDA describes seven days at each of two temperature ranges as an example. | Suitable temperature and sufficient time, generally not less than 14 days; manipulation should ensure media contacts internal surfaces. | Scientifically justified incubation, handling, inspection and data interpretation within the complete APS program. |
| Contaminated units | Target is zero. FDA provides investigation/revalidation expectations based on batch size and number of positives. | The target is zero growth; any contaminated unit results in a failed APS and requires investigation. | Emphasizes detection, investigation, organism characterization and assessment of process impact. |
Final protocol requirements must be based on the applicable regulations, current approved guidance, product/process risk and the facility’s Quality System. This summary is not a substitute for protocol-specific regulatory assessment.
Programs We Support
Built for sophisticated aseptic operations.
Frequently Asked Questions
Media-fill support, explained.
Is a pharmaceutical media fill different from a pharmacy media fill?
The underlying purpose is similar, but pharmaceutical and 503B programs may involve longer processes, larger unit counts, multiple shifts, automated equipment, complex interventions, extensive environmental monitoring and FDA or global regulatory expectations. The APS must represent the actual process and its risks.
Why test growth promotion before the media fill?
Pre-fill growth promotion provides evidence that the selected media lot can recover appropriate microorganisms before production time and an entire simulation lot are committed. Post-incubation growth promotion is still needed to demonstrate that the medium retained its growth-supporting capability through the study.
Does PlumGXP have capacity to incubate the entire lot?
Yes. PlumGXP is positioning dedicated controlled capacity for complete APS lots throughout the required incubation period. Project planning confirms unit count, container size, temperature sequence, timing and segregation before the fill.
Why must units be checked during incubation?
Defined interim observations help identify suspected growth, damaged containers, incubation deviations or handling issues while the study is in progress. They supplement—not replace—the qualified final inspection of every integral unit.
Does every vial need to be inverted?
The objective is to ensure the medium contacts all internal container and closure surfaces. Inversion or swirling is commonly used for clear vials, but the exact manipulation should be appropriate for the container and defined in the approved protocol.
What happens if one unit shows growth?
It must be treated as significant. Under EU GMP Annex 1, any contaminated unit is a failed APS. A comprehensive investigation should include organism identification and review of interventions, personnel, environmental monitoring, incubation, container integrity and process records. The required corrective action and repeat simulations depend on the applicable framework and investigation outcome.
Can PlumGXP provide personnel and environmental monitoring onsite?
Yes. We can support viable air, surface, personnel and nonviable particle monitoring during the APS, with samples tied to time, location, operator, intervention and process phase so the data can support meaningful investigation and final reporting.
Do not let incubation capacity or limited microbiology resources weaken the validation.
Bring PlumGXP into the planning phase so growth promotion, monitoring, incubation, inspection and reporting operate as one controlled program.
Plan Your APS With PlumGXP →Technical framework: FDA Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing; EU GMP Annex 1: Manufacture of Sterile Medicinal Products; and PDA Technical Report No. 22 (Revised 2025). Requirements should be confirmed against the current source documents and the approved site procedure.